The company's peptide and nucleic treatments are designed to simulate the actions of the body's natural T-cells. This unique approach can produce off-the-shelf vaccine candidates that can be geiven regardless of HLA type.

The company's technologies can be used as stand-alone medications or in combination with other treatment modalities.

TapImmune has announced a proposed merger with Marker Therapeutics, a privately-held clinical stage developer of a transformative, non-genetically engineered, multi-antigen T cell therapy platform, which will add a significant portfolio of clinical-stage cell therapies to create a leading immuno-oncology pipeline.